Company: Chinook Therapeutics
Job title: Head of Renal Discovery & Translational Medicine
Andrew is the Head of Renal Discovery and Translational Medicine at Chinook Therapeutics. Prior to Chinook, Andrew was Senior Director of Discovery and Translational Biology at Ardelyx, where he and his teams played key roles in delivering small molecule candidates for the treatment of cardio-renal diseases, as well as elucidating the novel molecular mechanism of action of tenanapor, currently in late-stage clinical development for the treatment of hyperphosphatemia in dialysis patients. Previously, Andrew led the Renal Discovery scientific strategy to treat chronic kidney disease at AbbVie. Andrew received his Ph.D in pharmacology from Michigan State University and completed training in Veterinary Medicine and Surgery at Murdoch University in Australia.
Selective ETA receptor antagonist ATRASENTAN for the Treatment of Primary Glomerular Diseases 9:30 am
day: Day Two
Panel Discussion: Executing Precision Medicine in Clinical Trials 4:30 pm
day: Day One